Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer

• Published in: Pharmaceutics Vol. 15; no. 7; p. 1788
• Main Authors: Ye, Wei, Li, Meiye, Luo, Kewang
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.06.2023; MDPI
• Subjects: B cells; Cancer therapies; Cytokines; Cytotoxicity; Dendritic cells; Development and progression; Drug approval; FDA approval; Health aspects; immune cells; Immune system; immunotherapies; Immunotherapy; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Lymphocytes; Medical prognosis; Metastasis; Mortality; NSCLC; Pharmaceutical industry; Review; TME; Tumors; United States; immunotherapies; immune cells; NSCLC; TME
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15071788

The tumor microenvironment (TME) plays critical roles in immune modulation and tumor malignancies in the process of cancer development. Immune cells constitute a significant component of the TME and influence the migration and metastasis of tumor cells. Recently, a number of therapeutic approaches targeting immune cells have proven promising and have already been used to treat different types of cancer. In particular, PD-1 and PD-L1 inhibitors have been used in the first-line setting in non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%, as approved by the FDA. In this review, we provide an introduction to the immune cells in the TME and their efficacies, and then we discuss current immunotherapies in NSCLC and scientific research progress in this field.